MedTrace Logo

Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone

NCT01332370 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5391

Last updated 2017-06-02

No results posted yet for this study

Summary

This retrospective database study analyzed resource utilization and costs associated with sitagliptin (STG) in comparison with rosiglitazone (RSG) added to metformin (MET) monotherapy among adults with a diagnosis of diabetes who were continuously enrolled in a large US healthcare plan.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Rosiglitazone + Metformin

At least 180 days of continuous therapy with RSG+MET after the first Rx for RSG

DRUG

Sitagliptin + Metformin

At least 180 days of continuous therapy with STG+MET after the first Rx for STG

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2010-12-31
Completion
2010-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01332370 on ClinicalTrials.gov